Fecal microbiota transplant (FMT) as a treatment for C. difficile infections has skyrocketed over the past decade. While it has saved tens of thousands of lives, FMT remains controversial and the Food and Drug Administration (FDA) has been slow to formalize its regulatory status. This has left doctors, scientists, drug developers and, most importantly patients, operating in a regulatory fog.

Peggy Lillis Foundation hosted this educational webinar with leading scholar Diane Hoffmann to unpack the past, the present, and possible futures for FDA regulation of FMT and other microbiome- derived treatments.